Seres Therapeutics (MCRB) Enterprise Value (2015 - 2026)

Seres Therapeutics has disclosed Enterprise Value across 12 years of filings, most recently posting $61.9 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 19.39% year-over-year to $61.9 million; the TTM figure through Jun 2026 stood at $61.9 million (up 19.39% YoY), while the FY2025 annual figure was $96.4 million, down 14.64% from the prior year.
• Enterprise Value came in at $61.9 million for Q2 2026 at Seres Therapeutics, up from $55.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $611.2 million in Q1 2023 to a low of $6.0 million in Q1 2024.
• Average Enterprise Value over 5 years is $184.3 million, with a median of $95.3 million recorded in 2024.
• Year-over-year, Enterprise Value tumbled 99.01% in 2024 and surged 951.06% in 2025.
• Over 5 years, Enterprise Value stood at $519.9 million in 2022, then tumbled by 88.25% to $61.1 million in 2023, then soared by 84.93% to $113.0 million in 2024, then decreased by 14.64% to $96.4 million in 2025, then slumped by 35.76% to $61.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $61.9 million in Q2 2026, $55.2 million in Q1 2026, and $96.4 million in Q4 2025.